Navigation Links
New diagnostic marker for prostate cancer

Researchers of the University of Michigan, have found a gene which acts as a specific diagnostic marker for prostate cancer. Using a technique called DNA microarray analysis, which allows investigation of the activity of thousands of different genes in tissue samples. //The gene is called a-methylacyl-CoA racemase (AMACR) and it's never before been seen in association with cancer.

In this study, AMACR was found in over 90 per cent of 200 prostate cancer tissue samples. Importantly, it was not seen in benign prostate tissue or other tissue showing non-malignant change. There's no suggestion that AMACR actually causes cancer, but it does act as a marker showing that cancer is present.

It may well be that AMACR will score over the conventional prostate specific antigen (PSA) screen for prostate cancer. For PSA is found in cancer but also in benign prostate disease. AMACR looks to be far more specific. And the researchers have found the gene in other cancers too, such as colorectal, ovarian and breast cancer, which suggests it may be widely applicable as an accurate diagnostic test.


'"/>




Page: 1

Related medicine news :

1. MRI as a diagnostic tool for breast cancer
2. Mammography units and up gradation and tax cuts on diagnostic equipments in Hospitals
3. SRL Ranbaxy offers quicker bird flu diagnostic test
4. Scientists Use Salivas diagnostic Alphabets to Diagnose Disease
5. Scientific markers of aging described
6. Tumour marker for melanoma found
7. Osteoporosis and kidney stones gene marker identified
8. New heart disease marker
9. Biomarker for prostate cancer may be separated for treatment
10. Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available
11. Molecular markers for early diagnosis of breast and ovarian cancer
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ccording to the World Health Organization (WHO) ex...tment is necessary for complete eradication of the...Asia in the next five-ten // years. WHO has ident...lymphatic filariasis (LF), visceral leishmaniasis ...
...n a step which is expected to alleviate the nation...rsing professors, allowing nursing schools to enro...n has awarded // $995,000 to the Medical College o... its new doctorate of nursing practice program, th...
...cientists in past centuries called the sickness by... the supposedly disease-bearing zephyrs wafting fr...spread by mosquitos. // And they say ill winds are...o halt the spread of a disease that kills 1 millio...
...he state-run Indira Gandhi Medical College (IGMC) ...s on patients in Himachal Pradesh. 'The IGMC hospi...st equipment including light monitoring system, li... light, automatic operation bed and latest x-ray m...
Other Medicine News:Health News:Concerted Effort Imperative For Elimination Of Tropical Diseases: WHO 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Malaria Vaccine May Be 10 Years Away 2Health News:Malaria Vaccine May Be 10 Years Away 3
(Date:9/3/2008)...ldren Studied. Wrong,Conclusions Reached., NIXA, ...for Disease,Control and Prevention (CDC) study rel...R vaccine and autism. The National Autism Associat...he growing public concern over a,vaccine-autism co...esign,and methodology., For years, parents have c...
(Date:9/3/2008)...ically infected Hepatitis C,patients strongly conf...008, - Study is the first to show a statisticall...t of therapeutic Hepatitis C vaccination, - Data...ond generation, vaccine formulated with Intercell... activation, VIENNA, Austria, S...
(Date:9/3/2008)...-- Panacea Pharmaceuticals,Inc. today announced t...ng,antibodies against human aspartyl (asparaginyl)...er biomarker and therapeutic target. These antibod...chusetts Institute of,Technology (MIT) and Panacea...r development of human cancer diagnostics and ther...
(Date:9/3/2008)...o Launch Progress and Adlea ...e Call Today at 11:30 am ET, SOUTH SAN FRANCISCO,...,Inc. (Nasdaq: ANSV ) announced today that the c...mercial and late-stage product development to,acce...l pain management,company. The company also provid...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 1American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 2American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 3American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 4American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 5American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 6American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 7American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 8American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 9American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 10American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 11American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 12American Physicians Capital Inc Reports Third Quarter 2007 Results 4632 13AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 1AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 2AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 3AEterna Zentaris to Further Develop Three Follow up Multi targeted Cytotoxic Candidates to AEZS 112 as Potential Novel Cancer Treatment 1512 4BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 1BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP 1 Gene in Multiple Cancer Types 668 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 1Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 2Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization 665 3
...y shows paroxetine produced no significant drug in... 2007 /PRNewswire/ -- After administration of,pali...ls of the,drug were not affected when given with a...ented today at the 160th Annual Meeting,of the Ame...tive,serotonin reuptake inhibitor (SSRI), is an an...
...AGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ --...ntly completed animal,study, a DNA vaccine formula...vant and delivered by needle-free injection,yielde...unformulated DNA vaccine delivered by needle and s...n following injection of,unformulated vaccine yiel...
Other Medicine Technology:Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 2Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 3Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 4Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 5Blood Levels of Paliperidone Extended-Release Tablets are Not,Increased by Common Antidepressant 6Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
The CRW system is the premier stereotactic system. The CRW system can be configured as a basic CT-only system, a CT/MR scanner-dependent system, or a high-level CT/MR scanner-independent system with
Table-mounted, retraction for radiolucent anterior spine procedures. Fully-adjustable for any approach and any patient. Combine with our radiolucent blade kit for optimal visibility.
Corlok Allografts are unique corticocancellous allografts comprised of an anterior cortical face and a unique Dovetail geometry permitting a precise interlocking fit with adjacent vertebrae. Corlok A
Solid cortical spacers with a natural anatomic fibular shape.
Medicine Products: